Netherlands· NL-f00735642693
Yorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde pen
A palopegteriparatide product containing palopegteriparatide, registered in Netherlands by Ascendis Pharma A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PALOPEGTERIPARATIDE
- Manufacturer
- Ascendis Pharma A/S
- Country
- Netherlands (NL)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1766
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- FranceYORVIPATH 168 microgrammes/0,56 mL, solution injectable en stylo prérempliASCENDIS PHARMA BONE DISEASES (DANEMARK)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ad7de2c9-9441-45a1-8499-807dd1f0a310 GET /v1/drugs/ad7de2c9-9441-45a1-8499-807dd1f0a310?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/yorvipath-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Palopegteriparatide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130783",
"excipients": [
"BARNSTEENZUUR (E 363)",
"MANNITOL (D-) (E 421)",
"METACRESOL",
"NATRIUMHYDROXIDE (E 524)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"PALOPEGTERIPARATIDE"
],
"leaflet_url": null,
"authorised_at": "2023/11/17",
"procedure_number": "EMEA/H/C/005934",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1766",
"additional_monitoring": "Y"
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.